Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews

Open Access 11-03-2024 | Cytostatic Therapy | Comment

The fibro-adipogenic progenitor APOD+DCN+LUM+ cell population in aggressive carcinomas

Authors: Lingyi Cai, Mikhail G. Kolonin, Dimitris Anastassiou

Published in: Cancer and Metastasis Reviews

Login to get access

Abstract

We identified a progenitor cell population highly enriched in samples from invasive and chemo-resistant carcinomas, characterized by a well-defined multigene signature including APOD, DCN, and LUM. This cell population has previously been labeled as consisting of inflammatory cancer-associated fibroblasts (iCAFs). The same signature characterizes naturally occurring fibro-adipogenic progenitors (FAPs) as well as stromal cells abundant in normal adipose tissue. Our analysis of human gene expression databases provides evidence that adipose stromal cells (ASCs) are recruited by tumors and undergo differentiation into CAFs during cancer progression to invasive and chemotherapy-resistant stages.
Appendix
Available only for authorised users
Literature
1.
Caligiuri, G., & Tuveson, D. A. (2023). Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell, 41, 434–449.CrossRefPubMed
2.
Vijay, J., et al. (2020). Single-cell analysis of human adipose tissue identifies depot- and disease-specific cell types. Nature Metabolism, 2, 97–109.CrossRefPubMedADS
3.
Rubenstein, A. B., et al. (2020). Single-cell transcriptional profiles in human skeletal muscle. Scientfic Reports, 10, 229.CrossRefADS
4.
Sastourné-Arrey, Q., et al. (2023). Adipose tissue is a source of regenerative cells that augment the repair of skeletal muscle after injury. Nature Communications, 14, 80.CrossRefPubMedPubMedCentralADS
5.
Cheng, W.-Y., Yang, O., & T.-H. & Anastassiou, D. (2013). Biomolecular events in cancer revealed by attractor metagenes. PLOS Computational Biology, 9, e1002920.CrossRefPubMedPubMedCentral
6.
Chen, Z., et al. (2020). Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nature Communications, 11, 5077.CrossRefPubMedPubMedCentralADS
7.
Hornburg, M., et al. (2021). Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell, 39, 928–944.e6.CrossRefPubMed
8.
9.
Cui Zhou, D., et al. (2022). Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Nature Genetics, 54, 1390–1405.CrossRefPubMedPubMedCentral
10.
Zhang, Y., et al. (2012). Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer Research, 72, 5198–5208.CrossRefPubMed
11.
Zhang, T., et al. (2016). CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nature Communications, 7, 11674.CrossRefPubMedPubMedCentralADS
12.
Öhlund, D., et al. (2017). Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Journal of Experimental Medicine, 214, 579–596.CrossRefPubMedPubMedCentral
13.
14.
Dominguez, C. X., et al. (2020). Single-cell rna sequencing reveals stromal evolution into lrrc15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discovery, 10, 232–253.CrossRefPubMed
15.
Elyada, E., et al. (2019). Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discovery, 9, 1102–1123.CrossRefPubMedPubMedCentral
16.
Thorlacius-Ussing, J., et al. (2023). The collagen landscape in cancer: profiling collagens in tumors and in circulation reveals novel markers of cancer-associated fibroblast subtypes. The Journal of Pathology, 262(1), 22–36.CrossRefPubMed
17.
Zhu, K., Cai, L., Cui, C., de Los Toyos, J. R., & Anastassiou, D. (2021). Single-cell analysis reveals the pan-cancer invasiveness-associated transition of adipose-derived stromal cells into COL11A1-expressing cancer-associated fibroblasts. PLOS Computational Biology, 17, e1009228.CrossRefPubMedPubMedCentral
18.
Kim, H., Watkinson, J., Varadan, V., & Anastassiou, D. (2010). Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Medical Genomics, 3, 51.CrossRefPubMedPubMedCentral
19.
Wang, Y., et al. (2021). Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discovery, 7, 1–17.CrossRefPubMedPubMedCentral
20.
21.
Lengyel, E., Makowski, L., DiGiovanni, J., & Kolonin, M. G. (2018). Cancer as a matter of fat: the crosstalk between adipose tissue and tumors. Trends Cancer, 4, 374–384.CrossRefPubMedPubMedCentral
Metadata
Title
The fibro-adipogenic progenitor APOD+DCN+LUM+ cell population in aggressive carcinomas
Authors
Lingyi Cai
Mikhail G. Kolonin
Dimitris Anastassiou
Publication date
11-03-2024
Publisher
Springer US
Published in
Cancer and Metastasis Reviews
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-024-10181-y
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits